Pressure-Volume Loop During High-Risk PCI

Sponsor
Henry Ford Health System (Other)
Overall Status
Recruiting
CT.gov ID
NCT04681313
Collaborator
Abiomed Inc. (Industry)
10
1
28.4
0.4

Study Details

Study Description

Brief Summary

This study will examine the physiologic effects on loading conditions and contractility of the left ventricle during high-risk primary coronary intervention (HRPCI) in the Cardiac Cath Lab.

This will be performed through analysis of real-time left ventricular (LV) pressure-volume loops (PVL) by continuously recording PVL during HRPCI with the Inca® Pressure-Volume Loop System that will be temporarily placed in the left ventricle during the procedure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: High-risk percutaneous coronary intervention

Detailed Description

Given the complexity of patients treated by high risk percutaneous coronary interventions (HRPCI), mechanical circulatory support (MCS) devices are increasingly used to maintain hemodynamic stability during these procedures. It is crucial to have a better understanding of the hemodynamic effects during HRPCI and of MCS devices to guide appropriate device selection and utilization for HRPCI.

Clinical studies evaluating different MCS devices are not all consistent in terms of patient selection, outcomes examined and overall findings. Therefore, the role of MCS devices in HRPCI is still widely debated. This is reflected in a variable clinical practice pattern and recommendations from professional society guidelines. The investigators believe that having a clear scientific understanding of MCS devices in terms of hemodynamic effects during different stages of these complex procedures may prove helpful in refining the process of appropriate MCS device selection in appropriate clinical setting.

One especially insightful method of examining the MCS devices effect is analyzing the left ventricular (LV) pressure-volume loops (PVL). Continuously recording PVL during HRPCI can provide valuable data on the device effects on loading conditions and contractility of the left ventricle.

In this study, the investigators will collect hemodynamic data in real-time during HRPCI being performed as standard of care and continuously recording left ventricular pressure-volume loop (PVL) throughout the procedure via the Inca® Pressure-Volume Loop System (CD Leycom, Hengelo, The Netherlands).

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Pressure-Volume Loop During PCI: Real-Time Left Ventricular Pressure-Volume Analysis in High-Risk PCI
Actual Study Start Date :
Apr 19, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Changes in left ventricular end diastolic pressure (LVEDP). [Immediate (during PCI).]

    Measured changes in left ventricular end diastolic pressure (LVEDP) as measured real-time by the Inca PV-Loop system.

  2. Changes in left ventricular end systolic pressure. [Immediate (during PCI).]

    Measured changes in left ventricular end systolic pressure as measured real-time by the Inca PV-Loop system.

  3. Changes in left ventricular compliance. [Immediate (during PCI).]

    Measured changes in left ventricular compliance as measured real-time by the Inca PV-Loop system.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients (18 years and older) with known coronary artery disease and planned elective HRPCI procedures.
Exclusion Criteria:
  • Any patient not considered appropriate for elective HRPCI procedures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Henry Ford Hospital Detroit Michigan United States 48202

Sponsors and Collaborators

  • Henry Ford Health System
  • Abiomed Inc.

Investigators

  • Principal Investigator: William O'Neill, MD, Henry Ford Health System
  • Study Director: Mohammad Alqarqaz, MD, Henry Ford Health System
  • Study Director: Mir Babar Basir, DO, Henry Ford Health System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
William W. O'Neill, Director, Center for Structural Heart Disease, Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT04681313
Other Study ID Numbers:
  • 9809
First Posted:
Dec 23, 2020
Last Update Posted:
Feb 9, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by William W. O'Neill, Director, Center for Structural Heart Disease, Henry Ford Health System
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2022